It is known from previous reports in the literature that inhibition of ASCT2 in prostate cancer is accompanied by decreased glutamine uptake, which significantly inhibits tumor growth and metastasis in vivo through the cell cycle progression of E2F transcription factors (Wang et al., 2015). The gene discussed is SLC1A5; the disease is prostate cancer.